Literature DB >> 12460615

Inhibition of neuronal Na+ channels by the novel antiepileptic compound DCUKA: identification of the diphenylureido moiety as an inactivation modifier.

Ze-Jun Wang1, Lawrence D Snell, Boris Tabakoff, Simon R Levinson.   

Abstract

In a previous analysis of existing antiseizure compounds, we suggested that a common diphenylureido moiety was responsible for the activity-dependent, Na(+) channel blocking actions of these drugs (L. D. Snell et al., 2000, J. Pharmacol. Exp. Ther. 292: 215-227). Thus the novel diphenylureido compound [N,N-(diphenyl)-4-ureido-5,7-dichloro-2-carboxyquinoline] DCUKA was developed to incorporate the diphenylureido pharmacophore into a structure that also acted as an NMDA receptor antagonist. DCUKA has previously been shown to have antiepileptic properties in animals, and in the present study the actions of DCUKA on Na(+) currents were characterized using transfected cells that stably expressed the rat brain Na(v)1.2 channel isoform. In whole-cell voltage-clamp recordings, DCUKA reduced Na(+) currents in a dose- and membrane potential-dependent fashion, with an apparent 1:1 stoichiometry of drug:channel interaction. Characterization of the effects of DCUKA on Na(+) channel function strongly suggested that DCUKA acts by enhancing Na(+) channel inactivation. Thus in the presence of DCUKA, Na(v)1.2 channels showed reduced availability in steady-state inactivation protocols, displayed use-dependent inhibition, and were slower to recover from inactivation than untreated channels, while DCUKA showed no significant interaction with the open state of the channel. As previously postulated for the anticonvulsants carbamazepine and phenytoin, these results could be well explained by a model in which the drug preferentially interacts with the fast inactivated state of the channel. Finally, DCUKA was generally more efficacious than carbamazepine in modifying sodium channel behavior. Thus the diphenylureido moiety identified by a structural analysis of classic anticonvulsants appears to be important to the inactivation-specific Na(+) channel inhibition by this class of antiseizure agents.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12460615     DOI: 10.1006/exnr.2002.8029

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  11 in total

1.  A pharmacophore derived phenytoin analogue with increased affinity for slow inactivated sodium channels exhibits a desired anticonvulsant profile.

Authors:  Paul W Lenkowski; Timothy W Batts; Misty D Smith; Seong-Hoon Ko; Paulianda J Jones; Catherine H Taylor; Ashley K McCusker; Gary C Davis; Hali A Hartmann; H Steve White; Milton L Brown; Manoj K Patel
Journal:  Neuropharmacology       Date:  2006-12-14       Impact factor: 5.250

2.  A novel substituted aminoquinoline selectively targets voltage-sensitive sodium channel isoforms and NMDA receptor subtypes and alleviates chronic inflammatory and neuropathic pain.

Authors:  Boris Tabakoff; Wenhua Ren; Lauren Vanderlinden; Lawrence D Snell; Christopher J Matheson; Ze-Jun Wang; Rock Levinson; C Thetford Smothers; John J Woodward; Yumiko Honse; David Lovinger; Anthony M Rush; William A Sather; Daniel L Gustafson; Paula L Hoffman
Journal:  Eur J Pharmacol       Date:  2016-05-05       Impact factor: 4.432

3.  A substituted anilino enaminone acts as a novel positive allosteric modulator of GABA(A) receptors in the mouse brain.

Authors:  Ze-Jun Wang; Liqin Sun; Patrice L Jackson; Kenneth R Scott; Thomas Heinbockel
Journal:  J Pharmacol Exp Ther       Date:  2010-12-16       Impact factor: 4.030

Review 4.  Medications development to treat alcohol dependence: a vision for the next decade.

Authors:  Raye Z Litten; Mark Egli; Markus Heilig; Changhai Cui; Joanne B Fertig; Megan L Ryan; Daniel E Falk; Howard Moss; Robert Huebner; Antonio Noronha
Journal:  Addict Biol       Date:  2012-03-28       Impact factor: 4.280

5.  Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels.

Authors:  Richard G Webster; Keith L Brain; Richard H Wilson; Jean L Grem; Angela Vincent
Journal:  Br J Pharmacol       Date:  2005-12       Impact factor: 8.739

Review 6.  Discovery, Development, and Adoption of Medications to Treat Alcohol Use Disorder: Goals for the Phases of Medications Development.

Authors:  Raye Z Litten; Daniel E Falk; Megan L Ryan; Joanne B Fertig
Journal:  Alcohol Clin Exp Res       Date:  2016-05-17       Impact factor: 3.455

7.  Inhibition of Nav1.7 channels by methyl eugenol as a mechanism underlying its antinociceptive and anesthetic actions.

Authors:  Ze-Jun Wang; Boris Tabakoff; Simon R Levinson; Thomas Heinbockel
Journal:  Acta Pharmacol Sin       Date:  2015-06-08       Impact factor: 6.150

Review 8.  Allosteric Modulation of GABAA Receptors by an Anilino Enaminone in an Olfactory Center of the Mouse Brain.

Authors:  Thomas Heinbockel; Ze-Jun Wang; Patrice L Jackson-Ayotunde
Journal:  Pharmaceuticals (Basel)       Date:  2014-12-17

9.  Resibufogenin and cinobufagin activate central neurons through an ouabain-like action.

Authors:  Ze-Jun Wang; Liqin Sun; Thomas Heinbockel
Journal:  PLoS One       Date:  2014-11-24       Impact factor: 3.240

10.  Identification of both GABAA receptors and voltage-activated Na(+) channels as molecular targets of anticonvulsant α-asarone.

Authors:  Ze-Jun Wang; Simon R Levinson; Liqin Sun; Thomas Heinbockel
Journal:  Front Pharmacol       Date:  2014-03-11       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.